

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

3

Complete if Known

Application Number	US 10/768,953
Filing Date	Jan. 29, 2004
First Named Inventor	Amedeo Leonardi
Art Unit	To Be Assigned 1614
Examiner Name	To Be Assigned L. ROYDS

Attorney Docket Number 20199/100M275-US1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.*	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
LAR	AA	US 5,462,942	10-31-1995	Hartog, et al.	
LAR	AB	US 6,071,920	06-06-2000	Leonardi, et al.	
LAR	AC	US 6,369,222 B1	04-09-2002	Binggeli, et al.	
LAR	AD	US 2003/0162777	08-28-2003	Leonardi, et al.	
LAR	AE	US 2003/0181446	09-25-2003	Leonardi, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.*	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴ -Number ⁵ -Kind Code ⁶ (if known)				
LAR	1.	WO 95/11891	05-04-1995	Astra Aktiebolag		
LAR	2.	WO 99/02497	01-21-1999	Novartis-Erfindungen Verwaltungsgesellschaft mbh		
LAR	3.	WO 99/06384	02-11-1999	Recordati S.A., Chemical and Pharmaceutical Company		
LAR	4.	WO 00/63166	10-26-2000	F. Hoffmann-La Roche AG		
LAR	5.	WO 00/69816	11-23-2000	Eli Lilly and Company		
LAR	6.	WO 01/12627	02-22-2001	NPS Pharmaceuticals, Inc.		
LAR	7.	WO 01/16121	03-08-2001	Merck & Co., Inc.		
LAR	8.	WO 01/27070	04-19-2001	F. Hoffmann-La Roche		
LAR	9.	WO 01/32632	05-10-2001	Eli Lilly and Company		
LAR	10.	WO 02/46166	08-13-2002	F. Hoffmann-La Roche		
LAR	11.	WO 02/062323	08-15-2002	Novartis AG		
LAR	12.	WO 02/068417	09-06-2002	A. Slassi		
LAR	13.	WO 02/092086	11-21-2002	F. Hoffmann-La Roche AG		
LAR	14.	WO 02/094795	11-28-2002	F. Hoffmann-La Roche AG		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LAR	15.	Andersson K.E. (1988) "Current Concepts in the Treatment of Disorders of Micturition", <i>Drugs</i> , 35:477-494	
LAR	16.	Carroll et al., (2001) "BAY36-7620: A Potent Non-Competitive mGlu1 Receptor Antagonist with Inverse Agonist Activity", <i>Molecular Pharmacology</i> , 59:965-973	
LAR	17.	Cheng and Prusoff (1973) "Relationship between the inhibition constant (K _i) and the concentration of inhibitor which causes 50 per cent inhibition (I ₅₀) of an enzymatic reaction", <i>Biochemical Pharmacology</i> , 22:3099-3108	

Examiner Signature

Date Considered

16 JAN 07



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

3

Complete If Known

Application Number	US 10/768,953
Filing Date	Jan. 29, 2004
First Named Inventor	Amedeo Leonardi
Art Unit	To Be Assigned 1614
Examiner Name	To Be Assigned - L. RONDS


Attorney Docket Number 20199/100M275-US1

LAR	18. Corti et al., (1998) "Cloning and characterization of alternative mRNA forms for the rat metabotropic glutamate receptors mGluR7 and mGluR8", <i>European Journal of Neuroscience</i> , 10:3629-3641
LAR	19. de Groat W. (1990) "Central neural control of the lower urinary tract", <i>Neurobiology of Incontinence</i> , Ciba Foundation Symposium, 151:27-56
LAR	20. de Groat et al., (1993) "Neurophysiology of Micturition and Its Modification in Animal Models of Human Disease," <i>Nervous Control of the Urogenital System</i> , pg. 227-290
LAR	21. De Lean et al., (1978) "Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves", <i>Amer. J. Physiol.</i> , 235:E97-E102
LAR	22. Dray A. (1985) "The Rat Urinary Bladder", <i>Journal of Pharmacological Methods</i> , 13:157-165
LAR	23. Gasparini et al. (1999) "2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist", <i>Neuropharmacology</i> , 38:1493-1503
LAR	24. Goodman & Gillman, (1996) "Biotransformation of Drugs", <i>The Pharmacological Basis of Therapeutics</i> , 9 th Ed. McGraw-Hill, pg. 11-17
LAR	25. Guarneri et al., (1991) "Effects of Different Drugs on the Cystometrogram in Conscious Rats", <i>Pharmacological Research</i> , 24:175-187
LAR	26. Guarneri et al., (1993) "Effects of Drugs Used in the Therapy of Detrusor Hyperactivity on the Volume-Induced Contractions of the Rat Urinary Bladder", <i>Pharmacological Research</i> , 27:173-187
LAR	27. Guarneri et al., (1994) "A review of flavoxate: pharmacology and mechanism of action", <i>Drugs of Today</i> , 30:91-98
LAR	28. Hermans et al., (1999) "Effects of varying the expression level of recombinant human mGlu1a receptors on the pharmacological properties of agonists and antagonists", <i>British Journal of Pharmacology</i> , 126:873-882
LAR	29. Hermans and Challiss (2001) "Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: prototypic family C G-protein-coupled receptors", <i>Biochem. J.</i> , 359:465-484
LAR	30. Hinoi et al., (2001) "Characterization with [³ H]quisqualate of group I metabotropic glutamate receptor subtype in rat central and peripheral excitable tissues", <i>Neurochemistry International</i> , 38:277-285
LAR	31. Hudtloff & Thomsen (1998) "Autoradiographic visualization of group III metabotropic glutamate receptors using [³ H]-L-2-amino-4-phosphonobutyrate", <i>British Journal of Pharmacology</i> , 124:971-977
LAR	32. Johnson et al., (1999) "[³ H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells", <i>Neuropharmacology</i> , 38:1519-1529
LAR	33. Kingston et al. (1995) "Pharmacological analysis of 4-Carboxyphenylglycine Derivatives: Comparison of Effects on mGluR ₆ and mGluR _{5a} Subtypes", <i>Neuropharmacology</i> , 34:887-894
LAR	34. Leonardi et al., (2001) "N-[2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-nitrophenyl) Cyclohexanecarboxamide: A Novel Pre- and Postsynaptic 5-Hydroxytryptamine1A Receptor Antagonist Active on the Lower Urinary Tract", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 299:1027-1037
LAR	35. Lepor H. (1993) "Medical therapy for benign prostatic hyperplasia", <i>Urology</i> , 42:483-501
LAR	36. Maggi et al., (1984) "Evidence for the Involvement of Arachidonic Acid Metabolites in Spontaneous and Drug-induced Contractions of Rat Urinary Bladder", <i>The Journal of</i>

Examiner Signature

Date Considered

16 JAN 07



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

3

Complete if Known

Application Number	US 10/768,953
Filing Date	Jan. 29, 2004
First Named Inventor	Amedeo Leonardi
Art Unit	To Be Assigned 1614
Examiner Name	To Be Assigned LROYDS

Attorney Docket Number 20199/100M275-US1

<i>LAR</i>	<i>LAR</i>	<i>Pharmacology and Experimental Therapeutics</i> , 230:500-513	
<i>LAR</i>	37.	Maggi et al., (1986) "Somatovesical and Vesicovesical Excitatory Reflexes in Urethane-Anaesthetized Rats", <i>Brain Research</i> , 380:83-93	
<i>LAR</i>	38.	Malherbe et al., (1999) "Cloning and functional expression of alternative spliced variants of the human metabotropic glutamate receptor 8", <i>Molecular Brain Research</i> , 67:201-210	
<i>LAR</i>	39.	McGuire E. (1986) "Neuromuscular Dysfunction of the Lower Urinary Tract", <i>Campbell's Urology</i> , 1:618-638	
<i>LAR</i>	40.	Moroni et al., (1997) "Pharmacological Characterization of 1-Aminoindan-1,5-dicarboxylic Acid, a Potent mGluR1 Antagonist", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 281:721-729	
<i>LAR</i>	41.	Mutel et al., (2000) "Characterization of [³ H]Quisqualate Binding to Recombinant Rat Metabotropic Glutamate 1a and 5a Receptors and to Rat and Human Brain Sections", <i>Journal of Neurochemistry</i> , 75:2590-2601	
<i>LAR</i>	42.	Nilvebrant L. (2001) "Clinical experiences with tolterodine", <i>Life Sciences</i> , 68:2549-2556	
<i>LAR</i>	43.	Ruffmann R. (1988) "A Review of Flavoxate Hydrochloride in the Treatment of Urge Incontinence", <i>The Journal of International Medical Research</i> , 16:317-330	
<i>LAR</i>	44.	Spooren et al., (2001) "Novel allosteric antagonists shed light on mglu receptors and CNS disorders", <i>TRENDS in Pharmacological Sciences</i> , 22:331-337	
<i>LAR</i>	45.	Thomsen et al., (1997) "Cloning and Characterization of a Metabotropic Glutamate Receptor, mGluR4b", <i>Neuropharmacology</i> , 36:21-30	
<i>LAR</i>	46.	Varney et al., (1999) "SIB-1757 and SIB-1893: Selective, Noncompetitive Antagonists of Metabotropic Glutamate Receptor Type 5", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 290:170-181	
<i>LAR</i>	47.	Wright et al., (2001) "[³ H]LY341495 Binding to Group II Metabotropic Glutamate Receptors in Rat Brain", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 298:453-460	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature

Date Considered

16 JAN 07



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

Complete If Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/768,953
				Filing Date	January 29, 2004
				First Named Inventor	Amedeo Leonardi
				Art Unit	1614
				Examiner Name	Not Yet Assigned <i>L. R. RYDZ</i>
Sheet	1	of	1	Attorney Docket Number	06485/100M275-US1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
—	—	—	—	—	—

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
LAR	1	WO 03/093236	11/13/2003	Euroceltique, S.A.		
LAR	2	WO 03/066595	08/14/2003	Euroceltique, S.A.		
LAR	3	WO 2004/002983	01/08/2004	Euroceltique, S.A.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
UAR	4	Tanaka et al. (2003), "Effects of a Selective Metabotropic Glutamate Receptor Agonist on the Micturition Reflex Pathway in Urethane-Anesthetized Rats," <i>Neurology and Urodynamics</i> 22: 611-616	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Amedeo Leonardi</i>	Date Considered	16 January 2007
--------------------	------------------------	-----------------	-----------------